nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—Hypophosphataemia—Sorafenib—liver cancer	0.0309	0.0319	CcSEcCtD
Terazosin—Cardiac failure—Sorafenib—liver cancer	0.0133	0.0138	CcSEcCtD
Terazosin—Pain in extremity—Sorafenib—liver cancer	0.013	0.0135	CcSEcCtD
Terazosin—Hypokalaemia—Sorafenib—liver cancer	0.0119	0.0123	CcSEcCtD
Terazosin—Nasopharyngitis—Sorafenib—liver cancer	0.0116	0.012	CcSEcCtD
Terazosin—Gastritis—Sorafenib—liver cancer	0.0115	0.0119	CcSEcCtD
Terazosin—Hypophosphataemia—Epirubicin—liver cancer	0.0114	0.0118	CcSEcCtD
Terazosin—Hypophosphataemia—Doxorubicin—liver cancer	0.0106	0.0109	CcSEcCtD
Terazosin—Erectile dysfunction—Sorafenib—liver cancer	0.0104	0.0107	CcSEcCtD
Terazosin—Jaundice—Sorafenib—liver cancer	0.00978	0.0101	CcSEcCtD
Terazosin—Epistaxis—Sorafenib—liver cancer	0.00947	0.00979	CcSEcCtD
Terazosin—Amblyopia—Epirubicin—liver cancer	0.00859	0.00888	CcSEcCtD
Terazosin—Tinnitus—Sorafenib—liver cancer	0.0084	0.00868	CcSEcCtD
Terazosin—Arrhythmia—Sorafenib—liver cancer	0.00805	0.00832	CcSEcCtD
Terazosin—Amblyopia—Doxorubicin—liver cancer	0.00795	0.00821	CcSEcCtD
Terazosin—Malnutrition—Sorafenib—liver cancer	0.00784	0.00811	CcSEcCtD
Terazosin—Dysgeusia—Sorafenib—liver cancer	0.00768	0.00794	CcSEcCtD
Terazosin—Vasodilation—Epirubicin—liver cancer	0.00755	0.0078	CcSEcCtD
Terazosin—Vasodilation procedure—Epirubicin—liver cancer	0.00755	0.0078	CcSEcCtD
Terazosin—Prazosin—CYP1A1—liver cancer	0.00752	1	CrCbGaD
Terazosin—Arthropathy—Epirubicin—liver cancer	0.00729	0.00754	CcSEcCtD
Terazosin—Cough increased—Epirubicin—liver cancer	0.00724	0.00749	CcSEcCtD
Terazosin—Angioedema—Sorafenib—liver cancer	0.00717	0.00741	CcSEcCtD
Terazosin—Syncope—Sorafenib—liver cancer	0.00703	0.00727	CcSEcCtD
Terazosin—Vasodilation—Doxorubicin—liver cancer	0.00698	0.00722	CcSEcCtD
Terazosin—Vasodilation procedure—Doxorubicin—liver cancer	0.00698	0.00722	CcSEcCtD
Terazosin—Loss of consciousness—Sorafenib—liver cancer	0.00689	0.00713	CcSEcCtD
Terazosin—Cough—Sorafenib—liver cancer	0.00684	0.00708	CcSEcCtD
Terazosin—Coordination abnormal—Epirubicin—liver cancer	0.00675	0.00698	CcSEcCtD
Terazosin—Arthropathy—Doxorubicin—liver cancer	0.00675	0.00697	CcSEcCtD
Terazosin—Musculoskeletal pain—Epirubicin—liver cancer	0.00671	0.00694	CcSEcCtD
Terazosin—Neck pain—Epirubicin—liver cancer	0.00671	0.00694	CcSEcCtD
Terazosin—Cough increased—Doxorubicin—liver cancer	0.0067	0.00693	CcSEcCtD
Terazosin—Myalgia—Sorafenib—liver cancer	0.00668	0.0069	CcSEcCtD
Terazosin—Arthralgia—Sorafenib—liver cancer	0.00668	0.0069	CcSEcCtD
Terazosin—Abnormal dreams—Epirubicin—liver cancer	0.00655	0.00677	CcSEcCtD
Terazosin—Dry mouth—Sorafenib—liver cancer	0.00653	0.00675	CcSEcCtD
Terazosin—Anaphylactic shock—Sorafenib—liver cancer	0.0064	0.00662	CcSEcCtD
Terazosin—Shock—Sorafenib—liver cancer	0.0063	0.00651	CcSEcCtD
Terazosin—Thrombocytopenia—Sorafenib—liver cancer	0.00627	0.00648	CcSEcCtD
Terazosin—Coordination abnormal—Doxorubicin—liver cancer	0.00625	0.00646	CcSEcCtD
Terazosin—Neck pain—Doxorubicin—liver cancer	0.00621	0.00642	CcSEcCtD
Terazosin—Musculoskeletal pain—Doxorubicin—liver cancer	0.00621	0.00642	CcSEcCtD
Terazosin—Anorexia—Sorafenib—liver cancer	0.0061	0.00631	CcSEcCtD
Terazosin—Abnormal dreams—Doxorubicin—liver cancer	0.00606	0.00627	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00583	0.00603	CcSEcCtD
Terazosin—Abnormal vision—Epirubicin—liver cancer	0.00578	0.00598	CcSEcCtD
Terazosin—Dyspnoea—Sorafenib—liver cancer	0.00571	0.0059	CcSEcCtD
Terazosin—Dyspepsia—Sorafenib—liver cancer	0.00563	0.00583	CcSEcCtD
Terazosin—Decreased appetite—Sorafenib—liver cancer	0.00556	0.00575	CcSEcCtD
Terazosin—Fatigue—Sorafenib—liver cancer	0.00552	0.00571	CcSEcCtD
Terazosin—Photosensitivity—Epirubicin—liver cancer	0.00548	0.00567	CcSEcCtD
Terazosin—Constipation—Sorafenib—liver cancer	0.00547	0.00566	CcSEcCtD
Terazosin—Pain—Sorafenib—liver cancer	0.00547	0.00566	CcSEcCtD
Terazosin—Abnormal vision—Doxorubicin—liver cancer	0.00535	0.00553	CcSEcCtD
Terazosin—Gastrointestinal pain—Sorafenib—liver cancer	0.00523	0.00541	CcSEcCtD
Terazosin—Photosensitivity—Doxorubicin—liver cancer	0.00507	0.00524	CcSEcCtD
Terazosin—Abdominal pain—Sorafenib—liver cancer	0.00506	0.00523	CcSEcCtD
Terazosin—Body temperature increased—Sorafenib—liver cancer	0.00506	0.00523	CcSEcCtD
Terazosin—Anaphylactoid reaction—Epirubicin—liver cancer	0.00497	0.00514	CcSEcCtD
Terazosin—Cardiac failure—Epirubicin—liver cancer	0.00493	0.0051	CcSEcCtD
Terazosin—Cerebrovascular accident—Epirubicin—liver cancer	0.00491	0.00508	CcSEcCtD
Terazosin—Pain in extremity—Epirubicin—liver cancer	0.00481	0.00498	CcSEcCtD
Terazosin—Osteoarthritis—Epirubicin—liver cancer	0.00481	0.00498	CcSEcCtD
Terazosin—Migraine—Epirubicin—liver cancer	0.00474	0.0049	CcSEcCtD
Terazosin—Hypersensitivity—Sorafenib—liver cancer	0.00472	0.00488	CcSEcCtD
Terazosin—Face oedema—Epirubicin—liver cancer	0.00465	0.0048	CcSEcCtD
Terazosin—Anaphylactoid reaction—Doxorubicin—liver cancer	0.0046	0.00476	CcSEcCtD
Terazosin—Asthenia—Sorafenib—liver cancer	0.00459	0.00475	CcSEcCtD
Terazosin—Cardiac failure—Doxorubicin—liver cancer	0.00456	0.00472	CcSEcCtD
Terazosin—Cerebrovascular accident—Doxorubicin—liver cancer	0.00454	0.0047	CcSEcCtD
Terazosin—Pruritus—Sorafenib—liver cancer	0.00453	0.00468	CcSEcCtD
Terazosin—Pain in extremity—Doxorubicin—liver cancer	0.00445	0.0046	CcSEcCtD
Terazosin—Osteoarthritis—Doxorubicin—liver cancer	0.00445	0.0046	CcSEcCtD
Terazosin—Orthostatic hypotension—Epirubicin—liver cancer	0.0044	0.00454	CcSEcCtD
Terazosin—Migraine—Doxorubicin—liver cancer	0.00438	0.00453	CcSEcCtD
Terazosin—Hypokalaemia—Epirubicin—liver cancer	0.00438	0.00453	CcSEcCtD
Terazosin—Diarrhoea—Sorafenib—liver cancer	0.00438	0.00453	CcSEcCtD
Terazosin—Nasopharyngitis—Epirubicin—liver cancer	0.0043	0.00445	CcSEcCtD
Terazosin—Face oedema—Doxorubicin—liver cancer	0.0043	0.00444	CcSEcCtD
Terazosin—Gastritis—Epirubicin—liver cancer	0.00426	0.0044	CcSEcCtD
Terazosin—Dizziness—Sorafenib—liver cancer	0.00423	0.00438	CcSEcCtD
Terazosin—Asthma—Epirubicin—liver cancer	0.00416	0.0043	CcSEcCtD
Terazosin—Influenza—Epirubicin—liver cancer	0.00416	0.0043	CcSEcCtD
Terazosin—Vomiting—Sorafenib—liver cancer	0.00407	0.00421	CcSEcCtD
Terazosin—Orthostatic hypotension—Doxorubicin—liver cancer	0.00407	0.00421	CcSEcCtD
Terazosin—Hypokalaemia—Doxorubicin—liver cancer	0.00405	0.00419	CcSEcCtD
Terazosin—Angina pectoris—Epirubicin—liver cancer	0.00405	0.00419	CcSEcCtD
Terazosin—Rash—Sorafenib—liver cancer	0.00404	0.00417	CcSEcCtD
Terazosin—Dermatitis—Sorafenib—liver cancer	0.00403	0.00417	CcSEcCtD
Terazosin—Headache—Sorafenib—liver cancer	0.00401	0.00415	CcSEcCtD
Terazosin—Bronchitis—Epirubicin—liver cancer	0.004	0.00414	CcSEcCtD
Terazosin—Nasopharyngitis—Doxorubicin—liver cancer	0.00398	0.00412	CcSEcCtD
Terazosin—Gastritis—Doxorubicin—liver cancer	0.00394	0.00407	CcSEcCtD
Terazosin—Dysuria—Epirubicin—liver cancer	0.00389	0.00402	CcSEcCtD
Terazosin—Influenza—Doxorubicin—liver cancer	0.00385	0.00398	CcSEcCtD
Terazosin—Asthma—Doxorubicin—liver cancer	0.00385	0.00398	CcSEcCtD
Terazosin—Pollakiuria—Epirubicin—liver cancer	0.00384	0.00397	CcSEcCtD
Terazosin—Nausea—Sorafenib—liver cancer	0.0038	0.00393	CcSEcCtD
Terazosin—Photosensitivity reaction—Epirubicin—liver cancer	0.0038	0.00393	CcSEcCtD
Terazosin—Weight increased—Epirubicin—liver cancer	0.00379	0.00391	CcSEcCtD
Terazosin—Angina pectoris—Doxorubicin—liver cancer	0.00375	0.00388	CcSEcCtD
Terazosin—Bronchitis—Doxorubicin—liver cancer	0.0037	0.00383	CcSEcCtD
Terazosin—Jaundice—Epirubicin—liver cancer	0.00362	0.00374	CcSEcCtD
Terazosin—Urinary tract infection—Epirubicin—liver cancer	0.00361	0.00373	CcSEcCtD
Terazosin—Conjunctivitis—Epirubicin—liver cancer	0.00361	0.00373	CcSEcCtD
Terazosin—Dysuria—Doxorubicin—liver cancer	0.0036	0.00372	CcSEcCtD
Terazosin—Sweating—Epirubicin—liver cancer	0.00356	0.00368	CcSEcCtD
Terazosin—Pollakiuria—Doxorubicin—liver cancer	0.00356	0.00368	CcSEcCtD
Terazosin—Photosensitivity reaction—Doxorubicin—liver cancer	0.00351	0.00363	CcSEcCtD
Terazosin—Weight increased—Doxorubicin—liver cancer	0.0035	0.00362	CcSEcCtD
Terazosin—Epistaxis—Epirubicin—liver cancer	0.0035	0.00362	CcSEcCtD
Terazosin—Sinusitis—Epirubicin—liver cancer	0.00348	0.0036	CcSEcCtD
Terazosin—Jaundice—Doxorubicin—liver cancer	0.00335	0.00346	CcSEcCtD
Terazosin—Rhinitis—Epirubicin—liver cancer	0.00334	0.00345	CcSEcCtD
Terazosin—Urinary tract infection—Doxorubicin—liver cancer	0.00334	0.00345	CcSEcCtD
Terazosin—Conjunctivitis—Doxorubicin—liver cancer	0.00334	0.00345	CcSEcCtD
Terazosin—Pharyngitis—Epirubicin—liver cancer	0.0033	0.00342	CcSEcCtD
Terazosin—Sweating—Doxorubicin—liver cancer	0.00329	0.0034	CcSEcCtD
Terazosin—Oedema peripheral—Epirubicin—liver cancer	0.00328	0.00339	CcSEcCtD
Terazosin—Epistaxis—Doxorubicin—liver cancer	0.00324	0.00335	CcSEcCtD
Terazosin—Sinusitis—Doxorubicin—liver cancer	0.00322	0.00333	CcSEcCtD
Terazosin—Visual impairment—Epirubicin—liver cancer	0.00321	0.00332	CcSEcCtD
Terazosin—Eye disorder—Epirubicin—liver cancer	0.00311	0.00322	CcSEcCtD
Terazosin—Tinnitus—Epirubicin—liver cancer	0.0031	0.00321	CcSEcCtD
Terazosin—Rhinitis—Doxorubicin—liver cancer	0.00309	0.00319	CcSEcCtD
Terazosin—Pharyngitis—Doxorubicin—liver cancer	0.00306	0.00316	CcSEcCtD
Terazosin—Oedema peripheral—Doxorubicin—liver cancer	0.00304	0.00314	CcSEcCtD
Terazosin—Arrhythmia—Epirubicin—liver cancer	0.00297	0.00308	CcSEcCtD
Terazosin—Visual impairment—Doxorubicin—liver cancer	0.00297	0.00307	CcSEcCtD
Terazosin—Malnutrition—Epirubicin—liver cancer	0.0029	0.003	CcSEcCtD
Terazosin—Eye disorder—Doxorubicin—liver cancer	0.00288	0.00298	CcSEcCtD
Terazosin—Tinnitus—Doxorubicin—liver cancer	0.00287	0.00297	CcSEcCtD
Terazosin—Flatulence—Epirubicin—liver cancer	0.00286	0.00295	CcSEcCtD
Terazosin—Tension—Epirubicin—liver cancer	0.00284	0.00294	CcSEcCtD
Terazosin—Dysgeusia—Epirubicin—liver cancer	0.00284	0.00293	CcSEcCtD
Terazosin—Nervousness—Epirubicin—liver cancer	0.00282	0.00291	CcSEcCtD
Terazosin—Back pain—Epirubicin—liver cancer	0.0028	0.0029	CcSEcCtD
Terazosin—Arrhythmia—Doxorubicin—liver cancer	0.00275	0.00285	CcSEcCtD
Terazosin—Vision blurred—Epirubicin—liver cancer	0.00273	0.00282	CcSEcCtD
Terazosin—Ill-defined disorder—Epirubicin—liver cancer	0.00269	0.00278	CcSEcCtD
Terazosin—Malnutrition—Doxorubicin—liver cancer	0.00268	0.00277	CcSEcCtD
Terazosin—Flatulence—Doxorubicin—liver cancer	0.00264	0.00273	CcSEcCtD
Terazosin—Tension—Doxorubicin—liver cancer	0.00263	0.00272	CcSEcCtD
Terazosin—Dysgeusia—Doxorubicin—liver cancer	0.00263	0.00272	CcSEcCtD
Terazosin—Malaise—Epirubicin—liver cancer	0.00261	0.0027	CcSEcCtD
Terazosin—Nervousness—Doxorubicin—liver cancer	0.0026	0.00269	CcSEcCtD
Terazosin—Vertigo—Epirubicin—liver cancer	0.0026	0.00269	CcSEcCtD
Terazosin—Syncope—Epirubicin—liver cancer	0.0026	0.00269	CcSEcCtD
Terazosin—Back pain—Doxorubicin—liver cancer	0.00259	0.00268	CcSEcCtD
Terazosin—Palpitations—Epirubicin—liver cancer	0.00256	0.00265	CcSEcCtD
Terazosin—Loss of consciousness—Epirubicin—liver cancer	0.00255	0.00263	CcSEcCtD
Terazosin—Cough—Epirubicin—liver cancer	0.00253	0.00261	CcSEcCtD
Terazosin—Vision blurred—Doxorubicin—liver cancer	0.00253	0.00261	CcSEcCtD
Terazosin—Convulsion—Epirubicin—liver cancer	0.00251	0.0026	CcSEcCtD
Terazosin—Ill-defined disorder—Doxorubicin—liver cancer	0.00249	0.00257	CcSEcCtD
Terazosin—Arthralgia—Epirubicin—liver cancer	0.00247	0.00255	CcSEcCtD
Terazosin—Chest pain—Epirubicin—liver cancer	0.00247	0.00255	CcSEcCtD
Terazosin—Myalgia—Epirubicin—liver cancer	0.00247	0.00255	CcSEcCtD
Terazosin—Anxiety—Epirubicin—liver cancer	0.00246	0.00254	CcSEcCtD
Terazosin—Discomfort—Epirubicin—liver cancer	0.00244	0.00252	CcSEcCtD
Terazosin—Malaise—Doxorubicin—liver cancer	0.00242	0.0025	CcSEcCtD
Terazosin—Dry mouth—Epirubicin—liver cancer	0.00241	0.0025	CcSEcCtD
Terazosin—Vertigo—Doxorubicin—liver cancer	0.00241	0.00249	CcSEcCtD
Terazosin—Syncope—Doxorubicin—liver cancer	0.00241	0.00249	CcSEcCtD
Terazosin—Confusional state—Epirubicin—liver cancer	0.00239	0.00247	CcSEcCtD
Terazosin—Palpitations—Doxorubicin—liver cancer	0.00237	0.00245	CcSEcCtD
Terazosin—Oedema—Epirubicin—liver cancer	0.00237	0.00245	CcSEcCtD
Terazosin—Anaphylactic shock—Epirubicin—liver cancer	0.00237	0.00245	CcSEcCtD
Terazosin—Loss of consciousness—Doxorubicin—liver cancer	0.00236	0.00244	CcSEcCtD
Terazosin—Cough—Doxorubicin—liver cancer	0.00234	0.00242	CcSEcCtD
Terazosin—Shock—Epirubicin—liver cancer	0.00233	0.00241	CcSEcCtD
Terazosin—Convulsion—Doxorubicin—liver cancer	0.00232	0.0024	CcSEcCtD
Terazosin—Thrombocytopenia—Epirubicin—liver cancer	0.00232	0.00239	CcSEcCtD
Terazosin—Tachycardia—Epirubicin—liver cancer	0.00231	0.00239	CcSEcCtD
Terazosin—Hyperhidrosis—Epirubicin—liver cancer	0.00229	0.00236	CcSEcCtD
Terazosin—Myalgia—Doxorubicin—liver cancer	0.00228	0.00236	CcSEcCtD
Terazosin—Chest pain—Doxorubicin—liver cancer	0.00228	0.00236	CcSEcCtD
Terazosin—Arthralgia—Doxorubicin—liver cancer	0.00228	0.00236	CcSEcCtD
Terazosin—Anxiety—Doxorubicin—liver cancer	0.00228	0.00235	CcSEcCtD
Terazosin—Discomfort—Doxorubicin—liver cancer	0.00226	0.00233	CcSEcCtD
Terazosin—Anorexia—Epirubicin—liver cancer	0.00226	0.00233	CcSEcCtD
Terazosin—Dry mouth—Doxorubicin—liver cancer	0.00223	0.00231	CcSEcCtD
Terazosin—Hypotension—Epirubicin—liver cancer	0.00221	0.00229	CcSEcCtD
Terazosin—Confusional state—Doxorubicin—liver cancer	0.00221	0.00228	CcSEcCtD
Terazosin—Oedema—Doxorubicin—liver cancer	0.00219	0.00226	CcSEcCtD
Terazosin—Anaphylactic shock—Doxorubicin—liver cancer	0.00219	0.00226	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00216	0.00223	CcSEcCtD
Terazosin—Shock—Doxorubicin—liver cancer	0.00215	0.00223	CcSEcCtD
Terazosin—Thrombocytopenia—Doxorubicin—liver cancer	0.00214	0.00222	CcSEcCtD
Terazosin—Insomnia—Epirubicin—liver cancer	0.00214	0.00221	CcSEcCtD
Terazosin—Tachycardia—Doxorubicin—liver cancer	0.00214	0.00221	CcSEcCtD
Terazosin—Paraesthesia—Epirubicin—liver cancer	0.00212	0.0022	CcSEcCtD
Terazosin—Hyperhidrosis—Doxorubicin—liver cancer	0.00212	0.00219	CcSEcCtD
Terazosin—Dyspnoea—Epirubicin—liver cancer	0.00211	0.00218	CcSEcCtD
Terazosin—Somnolence—Epirubicin—liver cancer	0.0021	0.00217	CcSEcCtD
Terazosin—Anorexia—Doxorubicin—liver cancer	0.00209	0.00216	CcSEcCtD
Terazosin—Dyspepsia—Epirubicin—liver cancer	0.00208	0.00215	CcSEcCtD
Terazosin—Decreased appetite—Epirubicin—liver cancer	0.00206	0.00213	CcSEcCtD
Terazosin—Hypotension—Doxorubicin—liver cancer	0.00205	0.00211	CcSEcCtD
Terazosin—Fatigue—Epirubicin—liver cancer	0.00204	0.00211	CcSEcCtD
Terazosin—Constipation—Epirubicin—liver cancer	0.00202	0.00209	CcSEcCtD
Terazosin—Pain—Epirubicin—liver cancer	0.00202	0.00209	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00199	0.00206	CcSEcCtD
Terazosin—Insomnia—Doxorubicin—liver cancer	0.00198	0.00205	CcSEcCtD
Terazosin—Paraesthesia—Doxorubicin—liver cancer	0.00197	0.00203	CcSEcCtD
Terazosin—Dyspnoea—Doxorubicin—liver cancer	0.00195	0.00202	CcSEcCtD
Terazosin—Feeling abnormal—Epirubicin—liver cancer	0.00195	0.00202	CcSEcCtD
Terazosin—Somnolence—Doxorubicin—liver cancer	0.00195	0.00201	CcSEcCtD
Terazosin—Gastrointestinal pain—Epirubicin—liver cancer	0.00193	0.002	CcSEcCtD
Terazosin—Dyspepsia—Doxorubicin—liver cancer	0.00193	0.00199	CcSEcCtD
Terazosin—Decreased appetite—Doxorubicin—liver cancer	0.0019	0.00197	CcSEcCtD
Terazosin—Fatigue—Doxorubicin—liver cancer	0.00189	0.00195	CcSEcCtD
Terazosin—Constipation—Doxorubicin—liver cancer	0.00187	0.00194	CcSEcCtD
Terazosin—Pain—Doxorubicin—liver cancer	0.00187	0.00194	CcSEcCtD
Terazosin—Body temperature increased—Epirubicin—liver cancer	0.00187	0.00193	CcSEcCtD
Terazosin—Abdominal pain—Epirubicin—liver cancer	0.00187	0.00193	CcSEcCtD
Terazosin—Feeling abnormal—Doxorubicin—liver cancer	0.0018	0.00186	CcSEcCtD
Terazosin—Gastrointestinal pain—Doxorubicin—liver cancer	0.00179	0.00185	CcSEcCtD
Terazosin—Hypersensitivity—Epirubicin—liver cancer	0.00174	0.0018	CcSEcCtD
Terazosin—Abdominal pain—Doxorubicin—liver cancer	0.00173	0.00179	CcSEcCtD
Terazosin—Body temperature increased—Doxorubicin—liver cancer	0.00173	0.00179	CcSEcCtD
Terazosin—Asthenia—Epirubicin—liver cancer	0.0017	0.00175	CcSEcCtD
Terazosin—Pruritus—Epirubicin—liver cancer	0.00167	0.00173	CcSEcCtD
Terazosin—Diarrhoea—Epirubicin—liver cancer	0.00162	0.00167	CcSEcCtD
Terazosin—Hypersensitivity—Doxorubicin—liver cancer	0.00161	0.00167	CcSEcCtD
Terazosin—Asthenia—Doxorubicin—liver cancer	0.00157	0.00162	CcSEcCtD
Terazosin—Dizziness—Epirubicin—liver cancer	0.00156	0.00162	CcSEcCtD
Terazosin—Pruritus—Doxorubicin—liver cancer	0.00155	0.0016	CcSEcCtD
Terazosin—Vomiting—Epirubicin—liver cancer	0.0015	0.00155	CcSEcCtD
Terazosin—Diarrhoea—Doxorubicin—liver cancer	0.0015	0.00155	CcSEcCtD
Terazosin—Rash—Epirubicin—liver cancer	0.00149	0.00154	CcSEcCtD
Terazosin—Dermatitis—Epirubicin—liver cancer	0.00149	0.00154	CcSEcCtD
Terazosin—Headache—Epirubicin—liver cancer	0.00148	0.00153	CcSEcCtD
Terazosin—Dizziness—Doxorubicin—liver cancer	0.00145	0.0015	CcSEcCtD
Terazosin—Nausea—Epirubicin—liver cancer	0.00141	0.00145	CcSEcCtD
Terazosin—Vomiting—Doxorubicin—liver cancer	0.00139	0.00144	CcSEcCtD
Terazosin—Rash—Doxorubicin—liver cancer	0.00138	0.00143	CcSEcCtD
Terazosin—Dermatitis—Doxorubicin—liver cancer	0.00138	0.00143	CcSEcCtD
Terazosin—Headache—Doxorubicin—liver cancer	0.00137	0.00142	CcSEcCtD
Terazosin—Nausea—Doxorubicin—liver cancer	0.0013	0.00134	CcSEcCtD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	2.53e-05	0.00101	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CSF2—liver cancer	2.49e-05	0.000988	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	2.47e-05	0.000983	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	2.42e-05	0.000964	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	2.39e-05	0.000952	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FST—liver cancer	2.38e-05	0.000945	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PRKCE—liver cancer	2.33e-05	0.000927	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	2.27e-05	0.000903	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TRIO—liver cancer	2.27e-05	0.000901	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CSF2—liver cancer	2.26e-05	0.000898	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—PIK3CA—liver cancer	2.26e-05	0.000897	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	2.2e-05	0.000873	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	2.19e-05	0.000872	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCR4—liver cancer	2.17e-05	0.000864	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	2.15e-05	0.000855	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PRKCE—liver cancer	2.12e-05	0.000842	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FST—liver cancer	2.11e-05	0.000839	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	2.1e-05	0.000836	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	2.09e-05	0.000832	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	2.09e-05	0.00083	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	2.07e-05	0.000824	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PRKCE—liver cancer	2.07e-05	0.000824	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADAM17—liver cancer	2.07e-05	0.000823	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CSF2—liver cancer	2.06e-05	0.00082	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	2.02e-05	0.000805	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	2.02e-05	0.000802	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	2.01e-05	0.000801	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TRIO—liver cancer	2.01e-05	0.000801	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	2.01e-05	0.0008	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	1.98e-05	0.000786	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—F2—liver cancer	1.95e-05	0.000776	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PSMA4—liver cancer	1.95e-05	0.000774	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PSMD10—liver cancer	1.95e-05	0.000774	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCR4—liver cancer	1.93e-05	0.000767	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GLUL—liver cancer	1.92e-05	0.000763	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CPT1B—liver cancer	1.92e-05	0.000763	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PRKCE—liver cancer	1.88e-05	0.000748	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CSF2—liver cancer	1.87e-05	0.000745	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CG—liver cancer	1.87e-05	0.000742	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	1.87e-05	0.000742	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NR1H4—liver cancer	1.85e-05	0.000736	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CSF2—liver cancer	1.83e-05	0.000729	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.82e-05	0.000725	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTA3—liver cancer	1.82e-05	0.000723	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	1.79e-05	0.00071	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—F2—liver cancer	1.77e-05	0.000704	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.75e-05	0.000696	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADAM17—liver cancer	1.72e-05	0.000683	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CG—liver cancer	1.7e-05	0.000674	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.68e-05	0.000667	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.67e-05	0.000666	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CSF2—liver cancer	1.66e-05	0.000662	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTA4—liver cancer	1.66e-05	0.000662	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CD—liver cancer	1.64e-05	0.000653	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTA2—liver cancer	1.62e-05	0.000645	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—F2—liver cancer	1.62e-05	0.000644	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PSMD10—liver cancer	1.62e-05	0.000642	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PSMA4—liver cancer	1.62e-05	0.000642	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTA1—liver cancer	1.56e-05	0.000622	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	1.56e-05	0.000622	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	1.55e-05	0.000617	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CG—liver cancer	1.55e-05	0.000616	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NAT2—liver cancer	1.55e-05	0.000615	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADAM17—liver cancer	1.53e-05	0.000607	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PRKCE—liver cancer	1.51e-05	0.000599	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CD—liver cancer	1.49e-05	0.000593	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALDOB—liver cancer	1.48e-05	0.00059	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—F2—liver cancer	1.47e-05	0.000585	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—F2—liver cancer	1.44e-05	0.000572	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PSMD10—liver cancer	1.43e-05	0.00057	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PSMA4—liver cancer	1.43e-05	0.00057	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CB—liver cancer	1.43e-05	0.000569	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IGF2—liver cancer	1.43e-05	0.000568	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.43e-05	0.000567	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CRABP1—liver cancer	1.42e-05	0.000563	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	1.41e-05	0.000562	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CG—liver cancer	1.41e-05	0.000559	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.38e-05	0.000548	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CG—liver cancer	1.38e-05	0.000547	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CD—liver cancer	1.36e-05	0.000542	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CSF2—liver cancer	1.33e-05	0.00053	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—RAF1—liver cancer	1.33e-05	0.000529	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—H2AFX—liver cancer	1.31e-05	0.000523	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—IL2—liver cancer	1.31e-05	0.000522	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—F2—liver cancer	1.31e-05	0.000519	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CB—liver cancer	1.3e-05	0.000517	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PRKCE—liver cancer	1.25e-05	0.000497	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CG—liver cancer	1.25e-05	0.000497	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CD—liver cancer	1.24e-05	0.000492	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HPGDS—liver cancer	1.24e-05	0.000492	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CD—liver cancer	1.21e-05	0.000481	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL2—liver cancer	1.19e-05	0.000474	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TERT—liver cancer	1.19e-05	0.000473	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CB—liver cancer	1.19e-05	0.000472	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IGF2—liver cancer	1.19e-05	0.000471	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.16e-05	0.000463	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PRKCE—liver cancer	1.11e-05	0.000442	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CSF2—liver cancer	1.11e-05	0.00044	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—RAF1—liver cancer	1.1e-05	0.000439	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PSMA4—liver cancer	1.1e-05	0.000438	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PSMD10—liver cancer	1.1e-05	0.000438	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CD—liver cancer	1.1e-05	0.000437	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—H2AFX—liver cancer	1.09e-05	0.000434	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—IL2—liver cancer	1.09e-05	0.000434	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KDR—liver cancer	1.09e-05	0.000432	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK14—liver cancer	1.08e-05	0.000429	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CB—liver cancer	1.08e-05	0.000429	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GOT2—liver cancer	1.07e-05	0.000426	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ESR1—liver cancer	1.06e-05	0.000421	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CB—liver cancer	1.05e-05	0.000419	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IGF2—liver cancer	1.05e-05	0.000419	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.05e-05	0.000418	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—F2—liver cancer	1.05e-05	0.000416	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2E1—liver cancer	1.01e-05	0.000401	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CG—liver cancer	1e-05	0.000398	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—APC—liver cancer	1e-05	0.000398	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL2—liver cancer	9.9e-06	0.000394	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TERT—liver cancer	9.87e-06	0.000392	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CSF2—liver cancer	9.83e-06	0.000391	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—RAF1—liver cancer	9.81e-06	0.00039	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—H2AFX—liver cancer	9.69e-06	0.000385	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—IL2—liver cancer	9.69e-06	0.000385	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CB—liver cancer	9.58e-06	0.000381	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	9.51e-06	0.000378	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYCS—liver cancer	9.43e-06	0.000375	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—BRAF—liver cancer	9.42e-06	0.000374	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GGT1—liver cancer	9.26e-06	0.000368	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GOT1—liver cancer	9.26e-06	0.000368	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KDR—liver cancer	9.03e-06	0.000359	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK14—liver cancer	8.97e-06	0.000356	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CD—liver cancer	8.81e-06	0.00035	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL2—liver cancer	8.8e-06	0.00035	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ESR1—liver cancer	8.8e-06	0.00035	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TERT—liver cancer	8.77e-06	0.000348	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—liver cancer	8.72e-06	0.000347	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SERPINE1—liver cancer	8.71e-06	0.000346	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—F2—liver cancer	8.69e-06	0.000345	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—KRAS—liver cancer	8.62e-06	0.000343	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTP1—liver cancer	8.32e-06	0.000331	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—APC—liver cancer	8.31e-06	0.000331	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CG—liver cancer	8.31e-06	0.000331	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HMOX1—liver cancer	8.2e-06	0.000326	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KDR—liver cancer	8.02e-06	0.000319	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK14—liver cancer	7.96e-06	0.000317	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—liver cancer	7.92e-06	0.000315	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAF1—liver cancer	7.86e-06	0.000313	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—BRAF—liver cancer	7.81e-06	0.000311	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ESR1—liver cancer	7.81e-06	0.000311	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—F2—liver cancer	7.72e-06	0.000307	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MTOR—liver cancer	7.68e-06	0.000305	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CB—liver cancer	7.68e-06	0.000305	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTM1—liver cancer	7.64e-06	0.000304	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—APC—liver cancer	7.38e-06	0.000294	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CG—liver cancer	7.38e-06	0.000294	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HRAS—liver cancer	7.33e-06	0.000291	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CD—liver cancer	7.31e-06	0.000291	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1A1—liver cancer	7.24e-06	0.000288	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	7.24e-06	0.000288	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	7.23e-06	0.000287	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1B—liver cancer	7.2e-06	0.000286	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—KRAS—liver cancer	7.16e-06	0.000284	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKT1—liver cancer	7.13e-06	0.000283	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CASP3—liver cancer	7.06e-06	0.000281	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL2—liver cancer	7.05e-06	0.00028	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—liver cancer	7.01e-06	0.000279	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—BRAF—liver cancer	6.94e-06	0.000276	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—liver cancer	6.87e-06	0.000273	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—JUN—liver cancer	6.86e-06	0.000273	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CTNNB1—liver cancer	6.81e-06	0.000271	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—MTHFR—liver cancer	6.75e-06	0.000268	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MMP9—liver cancer	6.67e-06	0.000265	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—liver cancer	6.65e-06	0.000264	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PPARA—liver cancer	6.63e-06	0.000263	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	6.57e-06	0.000261	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAF1—liver cancer	6.53e-06	0.000259	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	6.49e-06	0.000258	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MAPK8—liver cancer	6.49e-06	0.000258	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKT1—liver cancer	6.47e-06	0.000257	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	6.43e-06	0.000256	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	6.42e-06	0.000255	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MTOR—liver cancer	6.37e-06	0.000253	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	6.37e-06	0.000253	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—KRAS—liver cancer	6.36e-06	0.000253	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HRAS—liver cancer	6.08e-06	0.000242	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—liver cancer	5.99e-06	0.000238	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	5.98e-06	0.000238	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—STAT3—liver cancer	5.93e-06	0.000236	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	5.91e-06	0.000235	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CASP3—liver cancer	5.86e-06	0.000233	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL2—liver cancer	5.85e-06	0.000233	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	5.84e-06	0.000232	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—liver cancer	5.82e-06	0.000231	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAF1—liver cancer	5.8e-06	0.00023	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—liver cancer	5.7e-06	0.000227	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—JUN—liver cancer	5.69e-06	0.000226	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CG—liver cancer	5.67e-06	0.000226	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MTOR—liver cancer	5.66e-06	0.000225	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	5.66e-06	0.000225	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	5.65e-06	0.000225	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MMP9—liver cancer	5.54e-06	0.00022	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	5.52e-06	0.000219	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—liver cancer	5.51e-06	0.000219	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFB1—liver cancer	5.5e-06	0.000219	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PPARG—liver cancer	5.48e-06	0.000218	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HRAS—liver cancer	5.4e-06	0.000215	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MAPK8—liver cancer	5.39e-06	0.000214	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKT1—liver cancer	5.37e-06	0.000213	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	5.31e-06	0.000211	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	5.25e-06	0.000209	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CASP3—liver cancer	5.2e-06	0.000207	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL2—liver cancer	5.2e-06	0.000207	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—liver cancer	5.17e-06	0.000206	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KRAS—liver cancer	5.09e-06	0.000202	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—liver cancer	5.07e-06	0.000201	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—JUN—liver cancer	5.06e-06	0.000201	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	5.02e-06	0.000199	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CD—liver cancer	4.99e-06	0.000198	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—liver cancer	4.97e-06	0.000198	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALB—liver cancer	4.92e-06	0.000196	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—STAT3—liver cancer	4.92e-06	0.000196	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP9—liver cancer	4.92e-06	0.000196	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	4.9e-06	0.000195	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MAPK8—liver cancer	4.78e-06	0.00019	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKT1—liver cancer	4.77e-06	0.00019	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	4.68e-06	0.000186	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—liver cancer	4.57e-06	0.000182	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFB1—liver cancer	4.56e-06	0.000181	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—liver cancer	4.53e-06	0.00018	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—liver cancer	4.42e-06	0.000176	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—STAT3—liver cancer	4.37e-06	0.000174	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CB—liver cancer	4.35e-06	0.000173	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HRAS—liver cancer	4.33e-06	0.000172	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KRAS—liver cancer	4.23e-06	0.000168	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—liver cancer	4.14e-06	0.000165	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—liver cancer	4.06e-06	0.000162	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFB1—liver cancer	4.05e-06	0.000161	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	3.88e-06	0.000154	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKT1—liver cancer	3.82e-06	0.000152	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—liver cancer	3.76e-06	0.000149	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KRAS—liver cancer	3.75e-06	0.000149	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HRAS—liver cancer	3.59e-06	0.000143	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	3.45e-06	0.000137	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—liver cancer	3.44e-06	0.000137	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—liver cancer	3.34e-06	0.000133	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HRAS—liver cancer	3.19e-06	0.000127	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKT1—liver cancer	3.17e-06	0.000126	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—liver cancer	3.05e-06	0.000121	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKT1—liver cancer	2.82e-06	0.000112	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—liver cancer	2.65e-06	0.000105	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—AKT1—liver cancer	2.17e-06	8.61e-05	CbGpPWpGaD
